TABLE 1

Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or troglitazone

Placebo groupTroglitazone groupP
n122114
Clinical characteristics
 Age (years)34.3 ± 6.534.9 ± 6.60.52
 BMI (kg/m2)30.3 ± 5.330.6 ± 6.10.63
 Waist-to-hip circumference ratio0.86 ± 0.050.85 ± 0.060.19
 Using hormonal contraceptives*48%43%0.41
OGTT
 Fasting glucose (mg/dl)98.1 ± 9.198.7 ± 10.20.64
2-h glucose154.0 ± 24.0154.4 ± 27.00.97
 Total glucose area (mg/dl × min × 10−3)18.7 ± 2.018.9 ± 2.00.25
 Impaired glucose tolerance§72%69%0.66
 Fasting insulin (μU/ml)16.0 ± 7.517.0 ± 10.80.82
 Total insulin area (μU/ml × min)10,209 ± 55369,902 ± 65430.55
IVGTT
 Fasting glucose (mg/dl)94.3 ± 10.494.8 ± 10.20.71
Kg (min−1 × 100)1.48 ± 0.401.42 ± 0.390.23
 Fasting insulin (μU/ml)18.7 ± 9.716.6 ± 9.50.05
Si (min−1 per μU/ml × 10−4)#2.28 ± 1.752.64 ± 1.700.05
 AIRg (μU/ml × min)**569 ± 527454 ± 3600.18
 Total insulin area (units/ml × min)10,686 ± 56869,273 ± 54340.03
 DI (SI × AIRg)††983 ± 697976 ± 7170.99
  • Data are means ± SD. P values by two group t test for means, χ2, or Fisher’s exact test for proportions.

  • *

    * Combination oral contraceptives or depo-provera;

  • 75-g OGTT;

  • calculated by trapezoid method using data from entire duration of test;

  • §

    § plasma glucose 140–199 mg/dl 2 h after 75-g oral glucose load;

  • IVGTT, as described in research design and methods;

  • fractional glucose disappearance rate 10–40 min after glucose injection;

  • #

    # calculated by the Bergman minimal model (11);

  • **

    ** incremental insulin area 0–10 min after the glucose injection;

  • ††

    †† a measure of β-cell compensation for insulin resistance (9,14,15). To convert values for glucose to mmol/l, multiply by 0.05551. To convert values for insulin to pmol/l, multiply by 6.0.